Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines

PARP inhibitors (PARPi), such as Olaparib, have shown promising results in high-grade serous (HGS) epithelial ovarian cancer (EOC) treatment. PARPi sensitivity has been mainly associated with homologous recombination (HR) deficiency, but clinical trials have shown that predicting actual patient resp...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Fleury, Hubert, Carmona, Euridice, Morin, Vincent G., Meunier, Liliane, Masson, Jean-Yves, Tonin, Patricia N., Provencher, Diane, Mes-Masson, Anne-Marie
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5522225/
https://ncbi.nlm.nih.gov/pubmed/27374179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10308
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia